Published in J Virol on May 01, 1998
Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Mol Biol Cell (1999) 2.10
Role of the cytoplasmic tail of ecotropic moloney murine leukemia virus Env protein in fusion pore formation. J Virol (2000) 1.56
Modification of the cytoplasmic domain of influenza virus hemagglutinin affects enlargement of the fusion pore. J Virol (2000) 1.23
Activation of fusion by the SER virus F protein: a low-pH-dependent paramyxovirus entry process. J Virol (2003) 1.19
Deletion of the cytoplasmic tail of the fusion protein of the paramyxovirus simian virus 5 affects fusion pore enlargement. J Virol (2001) 1.17
Acylation-mediated membrane anchoring of avian influenza virus hemagglutinin is essential for fusion pore formation and virus infectivity. J Virol (2005) 1.14
Fatty acids on the A/USSR/77 influenza virus hemagglutinin facilitate the transition from hemifusion to fusion pore formation. J Virol (2002) 1.12
Chemoenzymatic site-specific labeling of influenza glycoproteins as a tool to observe virus budding in real time. PLoS Pathog (2012) 1.00
Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide. J Virol (2001) 0.98
The baculovirus GP64 protein mediates highly stable infectivity of a human respiratory syncytial virus lacking its homologous transmembrane glycoproteins. J Virol (2004) 0.97
Tight binding of influenza virus hemagglutinin to its receptor interferes with fusion pore dilation. J Virol (2002) 0.96
Influence of acylation sites of influenza B virus hemagglutinin on fusion pore formation and dilation. J Virol (2004) 0.95
Murine leukemia virus R Peptide inhibits influenza virus hemagglutinin-induced membrane fusion. J Virol (2006) 0.87
C-terminal tyrosine residues modulate the fusion activity of the Hendra virus fusion protein. Biochemistry (2011) 0.86
Multifaceted sequence-dependent and -independent roles for reovirus FAST protein cytoplasmic tails in fusion pore formation and syncytiogenesis. J Virol (2009) 0.85
A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus. J Virol (2005) 0.82
Effect of extension of the cytoplasmic domain of human immunodeficiency type 1 virus transmembrane protein gp41 on virus replication. J Virol (2004) 0.81
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 11.99
Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (1986) 10.62
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol (1985) 5.78
Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion. Cell (1994) 5.65
Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol (1996) 4.49
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol (1994) 3.59
Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin. J Cell Biol (1987) 3.52
GPI-anchored influenza hemagglutinin induces hemifusion to both red blood cell and planar bilayer membranes. J Cell Biol (1995) 3.34
Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes. FEBS Lett (1980) 3.27
Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide. Proc Natl Acad Sci U S A (1981) 3.13
pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry. J Virol (1994) 2.87
Kinetics of pH-dependent fusion between 3T3 fibroblasts expressing influenza hemagglutinin and red blood cells. Measurement by dequenching of fluorescence. J Biol Chem (1989) 2.82
Influenza viruses cause hemolysis and fusion of cells. Virology (1981) 2.73
Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types. J Virol (1992) 2.36
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol (1993) 2.34
Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular transport. J Virol (1994) 2.31
Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology (1993) 2.23
Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol (1994) 2.17
The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity. EMBO J (1994) 2.01
GPI- and transmembrane-anchored influenza hemagglutinin differ in structure and receptor binding activity. J Cell Biol (1993) 1.78
Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus. J Virol (1990) 1.75
Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation. EMBO J (1995) 1.74
Alterations to influenza virus hemagglutinin cytoplasmic tail modulate virus infectivity. J Virol (1992) 1.74
Site-specific mutagenesis identifies three cysteine residues in the cytoplasmic tail as acylation sites of influenza virus hemagglutinin. J Virol (1991) 1.65
Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis. EMBO J (1985) 1.64
Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity. Virology (1995) 1.62
Deacylation of the hemagglutinin of influenza A/Aichi/2/68 has no effect on membrane fusion properties. Virology (1991) 1.50
Fatty acids on the A/Japan/305/57 influenza virus hemagglutinin have a role in membrane fusion. EMBO J (1990) 1.48
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity. J Virol (1996) 1.41
Effects of altering palmitylation sites on biosynthesis and function of the influenza virus hemagglutinin. J Virol (1992) 1.37
Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: inhibitory effects of the R peptide. J Virol (1996) 1.35
The role of the cytoplasmic tail region of influenza virus hemagglutinin in formation and growth of fusion pores. Virology (1997) 1.31
Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formation. J Virol (1994) 1.30
Membrane rearrangements in fusion mediated by viral proteins. Trends Microbiol (1997) 1.02
Structure and assembly of hemagglutinin mutants of fowl plague virus with impaired surface transport. J Virol (1992) 1.01
Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence. Nat Genet (2000) 14.51
Activation of influenza A viruses by trypsin treatment. Virology (1975) 8.07
Haplotype sharing analysis using mantel statistics. Hum Hered (2005) 6.76
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34
Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J (1992) 5.05
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med (1999) 5.02
Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology (1976) 4.85
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16
Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. Immunity (1999) 3.69
Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology (1970) 3.58
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology (1979) 3.25
Small-bowel diverticulosis: perceptions and reality. J Am Coll Surg (1997) 3.09
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08
Presence of murine leukemia virus envelope proteins gp70 and p15(E) in a common polyprotein of infected cells. J Virol (1976) 2.91
Non-random radial higher-order chromatin arrangements in nuclei of diploid human cells. Chromosome Res (2001) 2.89
Inhibition of glycoprotein biosynthesis of influenza virus by D-glucosamine and 2-deoxy-D-glucose. Virology (1972) 2.84
Two independent targeting signals in the cytoplasmic domain determine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO J (1995) 2.76
Glycosphingolipids of plasma membranes of cultured cells and an enveloped virus (SV5) grown in these cells. Proc Natl Acad Sci U S A (1970) 2.73
Influenza viruses cause hemolysis and fusion of cells. Virology (1981) 2.73
Glycolipid content of vesicular stomatitis virus grown in baby hamster kidney cells. J Virol (1971) 2.68
The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity (1998) 2.68
The proteins of the parainfluenza virus SV5. 1. Separation of virion polypeptides by polyacrylamide gel electrophoresis. Virology (1969) 2.50
Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology (1994) 2.48
Lipids of plasma membranes of monkey and hamster kidney cells and of parainfluenza virions grown in these cells. Virology (1969) 2.48
Molecular biology and evolution of filoviruses. Arch Virol Suppl (1993) 2.45
Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med (1980) 2.39
Interactions of Marburg virus nucleocapsid proteins. Virology (1998) 2.37
The proteins of the parainfluenza virus SV5. II. The carbohydrate content and glycoproteins of the virion. Virology (1970) 2.37
Hearing preservation in acoustic neurinoma surgery. J Neurosurg (1992) 2.33
Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res (1992) 2.29
Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol (1996) 2.26
How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res (1998) 2.25
Pause on avian flu transmission research. Science (2012) 2.24
Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology (2000) 2.21
Rescue of vector-expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol (1994) 2.17
Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage. Virology (1981) 2.13
Glycosylation and oligomerization of the spike protein of Marburg virus. Virology (1991) 2.11
Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol (2000) 2.09
Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J Virol (1997) 2.09
Oscillatory synchrony between human extrastriate areas during visual short-term memory maintenance. J Neurosci (2001) 2.08
Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J (2000) 2.08
Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie (1994) 2.07
Association of influenza virus proteins with cytoplasmic fractions. Virology (1974) 2.00
Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage. Virology (1977) 2.00
Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector. EMBO J (1986) 1.98
Studies on the adaptation of influenza viruses to MDCK cells. EMBO J (1984) 1.98
The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology (1980) 1.97
Role of Staphylococcus protease in the development of influenza pneumonia. Nature (1987) 1.96
Neuromonitoring during surgery. Report of an IFCN Committee. Electroencephalogr Clin Neurophysiol (1993) 1.93
Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol (2001) 1.93
Laparoscopic nephrectomy: the experience of the laparoscopy working group of the German Urologic Association. J Urol (1998) 1.93
Influenza C virus uses 9-O-acetyl-N-acetylneuraminic acid as a high affinity receptor determinant for attachment to cells. J Biol Chem (1986) 1.92
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
An electron microscopic study of the presence or absence of neuraminic acid in enveloped viruses. Virology (1970) 1.88
The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl (1999) 1.87
Marburg virus gene 4 encodes the virion membrane protein, a type I transmembrane glycoprotein. J Virol (1993) 1.85
Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol (1995) 1.85
Biosynthesis and role of filoviral glycoproteins. J Gen Virol (2001) 1.84
Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation (1991) 1.83
Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology (1989) 1.81
Marburg and Ebola viruses. Adv Virus Res (1996) 1.81
Inhibition of glycosylation of the influenza virus hemagglutinin. J Virol (1974) 1.81
Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J Cell Biol (1994) 1.80
Hemagglutinin activation of pathogenic avian influenza viruses of serotype H7 requires the protease recognition motif R-X-K/R-R. Virology (1992) 1.79
Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein. J Virol (2000) 1.79
Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. J Mol Biol (2000) 1.79
The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. EMBO J (1985) 1.76
The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J Gen Virol (1995) 1.76
Long-term outcomes of chronic minimally conscious and vegetative states. Neurology (2010) 1.76
Fusion between cell membrane and liposomes containing the glycoproteins of influenza virus. Virology (1980) 1.73
Release of viral glycoproteins during Ebola virus infection. Virology (1998) 1.73
Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest (1995) 1.73
Post-translational glycosylation of coronavirus glycoprotein E1: inhibition by monensin. EMBO J (1982) 1.67
Site-specific mutagenesis identifies three cysteine residues in the cytoplasmic tail as acylation sites of influenza virus hemagglutinin. J Virol (1991) 1.65
Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature (1996) 1.65
Long-term efficacy of gamma knife radiosurgery in mesial temporal lobe epilepsy. Neurology (2008) 1.64
Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis. EMBO J (1985) 1.64
The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology (1998) 1.62
Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity. Virology (1995) 1.62
Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin. Virology (1995) 1.60
Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil (2003) 1.60
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol (2001) 1.59
Membrane association induces a conformational change in the Ebola virus matrix protein. EMBO J (2000) 1.59
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes. J Exp Med (1980) 1.58